Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial

• Published in: The Lancet (British edition) Vol. 359; no. 9325; pp. 2224 - 2229
• Main Authors: Lacy, Antonio M, García-Valdecasas, Juan C, Delgado, Salvadora, Castells, Antoni, Taurá, Pilar, Piqué, Josep M, Visa, Josep
• Format: Journal Article
• Language: English
• Published: London Elsevier Ltd 29-06-2002; Lancet; Elsevier Limited
• Subjects: Adenocarcinoma - mortality; Adenocarcinoma - surgery; Aged; Biological and medical sciences; Clinical trials; Colectomy - methods; Colectomy - statistics & numerical data; Colonic Neoplasms - mortality; Colonic Neoplasms - surgery; Colorectal cancer; Effectiveness; Female; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Laparoscopy; Male; Medical sciences; Morbidity; Mortality; Neoplasm Recurrence, Local; Postoperative Period; Proportional Hazards Models; Stomach, duodenum, intestine, rectum, anus; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Surgery; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the digestive system; Survival; Survival Analysis; Tumors; Adenocarcinoma; Human; Endoscopic surgery; Colectomy; Laparoscopy; Malignant tumor; Colonic disease; Surgery; Digestive diseases; Intestinal disease; Colon; Technique; Comparative study
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(02)09290-5

Although early reports on laparoscopy-assisted colectomy (LAC) in patients with colon cancer suggested that it reduces perioperative morbidity, its influence on long-term results is unknown. Our study aimed to compare efficacy of LAC and open colectomy (OC) for treatment of non-metastatic colon cancer in terms of tumour recurrence and survival.
From November, 1993, to July, 1998, all patients with adenocarcinoma of the colon were assessed for entry in this randomised trial. Adjuvant therapy and postoperative follow-up were the same in both groups. The main endpoint was cancer-related survival. Data were analysed according to the intention-to-treat principle.
219 patients took part in the study (111 LAC group, 108 OC group). Patients in the LAC group recovered faster than those in the OC group, with shorter peristalsis-detection (p=0·001) and oral-intake times (p=0·001), and shorter hospital stays (p=0·005). Morbidity was lower in the LAC group (p=0·001), although LAC did not influence perioperative mortality. Probability of cancer-related survival was higher in the LAC group (p=0·02). The Cox model showed that LAC was independently associated with reduced risk of tumour relapse (hazard ratio 0·39, 95% CI 0·19–0·82), death from any cause (0·48, 0·23–1·01), and death from a cancer-related cause (0·38, 0·16–0·91) compared with OC. This superiority of LAC was due to differences in patients with stage III tumours (p=0·04, p=0·02, and p=0·006, respectively).
LAC is more effective than OC for treatment of colon cancer in terms of morbidity, hospital stay, tumour recurrence, and cancer-related survival.